Interneuron dexfenfluramine advisory committee review to resume Nov. 16.
INTERNEURON DEXFENFLURAMINE ADVISORY COMMITTEE REDUX NOV. 16: FDA's Endocrinologic & Metabolic Drugs Advisory Committee will meet in November to resume discussion of the first long-term obesity therapy, oral dexfenfluramine, Lexington, Mass.-based Interneuron announced Oct. 3. Dexfenfluramine, tradenamed Redux, will be marketed by American Home Products if approved.
You may also be interested in...
US FDA’s plan to reconvene an advisory committee for a second look at Amylyx’ ALS drug AMX0035 is a remarkable twist in the ongoing review. It is essentially unprecedented, though there are two examples from the 1990s that offer some parallels.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials